前收市價 | 26.50 |
開市 | 41.43 |
買盤 | 19.00 |
賣出價 | 29.00 |
拍板 | 790.00 |
到期日 | 2025-12-19 |
今日波幅 | 26.50 - 41.43 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 41 |
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.